Related Experiment Video

Updated: Jun 2, 2025

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

6.8K

Current drug therapy for pleural mesothelioma

Hisao Imai1

  • 1Department of Respiratory Medicine, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-City, Saitama, 350-1298, Japan.

Respiratory Investigation
|January 16, 2025
PubMed

Insights

Pleural mesothelioma (PM) is a rare cancer linked to asbestos. Current treatments include chemotherapy and immunotherapy, with new combination therapies showing promise for improved survival.

Area of Science:

  • Oncology
  • Pulmonology
  • Toxicology

Background:

  • Pleural mesothelioma (PM) is a rare, aggressive malignancy of the pleural lining.
  • It typically arises from asbestos exposure, affecting mesothelial cells.
  • Median survival is poor, often around one year.

Purpose of the Study:

  • To review current systemic treatment options for advanced pleural mesothelioma.
  • To explore recent advancements in drug therapy for PM.
  • To discuss future therapeutic strategies and novel approaches.

Main Methods:

  • Literature review of current systemic therapies for advanced PM.
  • Analysis of first-line treatment regimens including chemotherapy and immunotherapy.
  • Exploration of emerging treatment paradigms and companion biomarkers.

Main Results:

  • First-line options for unresectable PM include cisplatin-pemetrexed and nivolumab-ipilimumab.
  • Recent advancements have introduced therapies that significantly improve patient survival.
  • Combination immunotherapy and chemotherapy represent promising future directions.

Conclusions:

  • Systemic therapy is crucial for advanced PM due to late presentation.
  • Novel approaches like chemo-immunotherapy and targeted agents are key for future treatment.
  • Tailoring therapies based on histologic and molecular diversity is essential for optimizing outcomes.
Keywords:
ChemotherapyImmune checkpoint inhibitorMesotheliomaSystemic therapiesTarget therapy

More Related Videos

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

1.8K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K

Related Concept Videos

Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
183
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
151
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
119
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
133